Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Ligand Pharmaceuticals's total assets was $2.24B at Sep 30, 2026. For fiscal 2025 it was $1.56B, up 65.7% from the year before. Over ten years it grew 12.0% a year on average. The highest annual figure on record is $1.56B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | +65.7% |
| FY2024 | Dec 31, 2024 | $941.77M | +19.6% |
| FY2023 | Dec 31, 2023 | $787.22M | +3.2% |
| FY2022 | Dec 31, 2022 | $762.67M | -41.2% |
| FY2021 | Dec 31, 2021 | $1.30B | -4.7% |
| FY2020 | Dec 31, 2020 | $1.36B | -8.9% |
| FY2019 | Dec 31, 2019 | $1.49B | +18.6% |
| FY2018 | Dec 31, 2018 | $1.26B | +87.9% |
| FY2017 | Dec 31, 2017 | $671.02M | +11.5% |
| FY2016 | Dec 31, 2016 | $601.59M | +19.6% |
| FY2015 | Dec 31, 2015 | $503.06M | +95.0% |
| FY2014 | Dec 31, 2014 | $258.03M | +146.4% |
| FY2013 | Dec 31, 2013 | $104.71M | +0.4% |
| FY2012 | Dec 31, 2012 | $104.26M | -13.5% |
| FY2011 | Dec 31, 2011 | $120.58M | +59.6% |
| FY2010 | Dec 31, 2010 | $75.56M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.24B | +51.5% |
| Q2 FY2026 | Jun 30, 2026 | $2.19B | +130.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.53B | +69.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.56B | +65.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.48B | +54.7% |
| Q2 FY2025 | Jun 30, 2025 | $948.60M | +9.5% |
| Q1 FY2025 | Mar 31, 2025 | $905.44M | -0.9% |
| Q4 FY2024 | Dec 31, 2024 | $941.77M | +19.6% |
| Q3 FY2024 | Sep 30, 2024 | $954.87M | +24.1% |
| Q2 FY2024 | Jun 30, 2024 | $866.41M | +14.3% |
| Q1 FY2024 | Mar 31, 2024 | $913.87M | +12.7% |
| Q4 FY2023 | Dec 31, 2023 | $787.22M | +3.2% |
| Q3 FY2023 | Sep 30, 2023 | $769.23M | -26.8% |
| Q2 FY2023 | Jun 30, 2023 | $758.11M | -29.6% |
| Q1 FY2023 | Mar 31, 2023 | $811.08M | -26.6% |
| Q4 FY2022 | Dec 31, 2022 | $762.67M | -41.2% |
| Q3 FY2022 | Sep 30, 2022 | $1.05B | -17.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.08B | -14.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.11B | -14.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.30B | -4.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.27B | +2.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.26B | +1.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.30B | +9.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.36B | -8.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.25B | -19.4% |
| Q2 FY2020 | Jun 30, 2020 | $1.24B | -31.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.19B | -38.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.49B | +18.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.55B | -26.5% |
| Q2 FY2019 | Jun 30, 2019 | $1.80B | -3.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.91B | +153.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.26B | +87.9% |
| Q3 FY2018 | Sep 30, 2018 | $2.11B | +217.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.86B | +190.3% |
| Q1 FY2018 | Mar 31, 2018 | $754.67M | +19.8% |
| Q4 FY2017 | Dec 31, 2017 | $671.02M | +11.5% |
| Q3 FY2017 | Sep 30, 2017 | $662.34M | – |
| Q2 FY2017 | Jun 30, 2017 | $640.02M | – |
| Q1 FY2017 | Mar 31, 2017 | $629.72M | – |
| Q4 FY2016 | Dec 31, 2016 | $601.59M | – |
See a number that looks wrong?